ASCO GI 2023 | Current and future targeted therapies in cholangiocarcinoma

Shubham Pant, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of current and upcoming targeted therapies in cholangiocarcinoma, including pemigatinib, infigratinib, and erdafitinib, which all target EFGR fusions. Ivosidenib was approved for IDH1-mutatued cholangiocarcinoma, and trastuzumab and pertuzumab have both shown encouraging efficacy in HER-2-positive cholangiocarcinoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.